RESEARCH

Open Access

Status of diagnosis and preventative treatment for primary headache disorders: real-world data of unmet needs in China



Huanxian Liu^{1,2†}, Ming Dong^{3†}, Kaiming Liu⁴, Zhihua Jia^{1,2}, Wei Gui⁵, Yingying Cheng³, Yudan Lv³, Kang Qu³, Hongru Zhao⁶, Jianjun Chen⁷, Dan Zhang⁸, Zhiliang Fan⁹, Xiaosu Yang¹⁰, Dongmei Hu¹¹, Hongyan Xie¹¹, Mingxin Li¹², Bing Wen¹², Sufen Chen¹³, Peng Xu¹⁴, Qingqing Rong¹⁴, Qiu He¹⁵, Zhanxiu Ren¹⁵, Fanhong Yan¹⁶, Heling Zhao¹⁶, Min Chen¹⁷, Tingmin Yu¹⁸, Hongli Qu¹⁹, Xingkai An¹⁹, Huailian Guo²⁰, Xinhua Zhang²⁰, Xiaoping Pan²¹, Xiaojuan Wang²¹, Shi Qiu²², Lvming Zhang²², Hongling Zhao²³, Xin Pan²³, Qi Wan²⁴, Lanyun Yan²⁴, Jing Liu^{1,2}, Zhe Yu^{1,2}, Mingjie Zhang^{1,2}, Ye Ran^{1,2}, Xun Han^{1,2}, Shengyuan Yu^{1,2*} and Zhao Dong^{1,2*}

Abstract

Background Headache disorders are widely prevalent and pose a considerable economic burden on individuals and society. Globally, misdiagnosis and inadequate treatment of primary headache disorders remain significant challenges, impeding the effective management of such conditions. Despite advancements in headache management over the last decade, a need for comprehensive evaluations of the status of primary headache disorders in China regarding diagnosis and preventative treatments persists.

Methods In the present study, we analyzed the established queries in the Survey of Fibromyalgia Comorbidity with Headache (SEARCH), focusing on previous diagnoses and preventative treatment regimens for primary headache disorders. This cross-sectional study encompassed adults diagnosed with primary headache disorders who sought treatment at 23 hospitals across China between September 2020 to May 2021.

Results The study comprised 2,868 participants who were systematically examined. Migraine and tension-type headaches (TTH) constituted a majority of the primary headache disorders, accounting for 74.1% (2,124/2,868) and 23.3% (668/2,868) of the participants, respectively. Medication overuse headache (MOH) affected 8.1% (231/2,868) of individuals with primary headache disorders. Over half of the individuals with primary headache disorders (56.6%, 1,624/2,868) remained undiagnosed. The previously correct diagnosis rates for migraine, TTH, TACs, and MOH were 27.3% (580/2,124), 8.1% (54/668), 23.2% (13/56), and 3.5% (8/231), respectively. The misdiagnosis of "Nervous headache" was found to be the most prevalent among individuals with migraine (9.9%, 211/2,124), TTH (10.0%, 67/668), trigeminal autonomic cephalalgias (TACs) (17.9%, 10/56), and other primary headache disorders (10.0%, 2/20)

[†]Huanxian Liu and Ming Dong these authors contributed equally to this work.

*Correspondence: Shengyuan Yu yusy1963@126.com Zhao Dong dong_zhaozhao@126.com Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.0/.

respectively. Only a minor proportion of individuals with migraine (16.5%, 77/468) and TTH (4.7%, 2/43) had received preventive medication before participating in the study.

Conclusions While there has been progress made in the rate of correct diagnosis of primary headache disorders in China compared to a decade ago, the prevalence of misdiagnosis and inadequate treatment of primary headaches remains a veritable issue. As such, focused efforts are essential to augment the diagnosis and preventive treatment measures related to primary headache disorders in the future.

Keywords Diagnosis, Treatment, Primary headache disorders, Migraine, Tension-type headache

Introduction

Primary headache disorders, which include migraine, tension-type headaches (TTH), trigeminal autonomic headaches (TACs), including cluster headaches, and other primary headaches disorders, pose a significant health concern [1]. Headache disorders, particularly migraine, TTH, and medication overuse headaches (MOH), are highly prevalent worldwide, and have the potential to cause significant disability, reduced quality of life, impaired productivity, as well as a significant economic burden on both individuals and society [2]. Correct diagnosis and appropriate treatment are critical in reducing the detrimental impacts of headache disorders on patients. However, misdiagnosis and inadequate treatment of primary headache disorders persist as considerable challenges [3].

In China, a population-based study unveiled that a significant proportion of patients with migraine or TTH had not received a correct diagnosis previously, with correct diagnosis rates of 13.8% and 5.6%, respectively [4, 5]. Similarly, a clinic-based study from the Chinese mainland indicated that just 13.5% of individuals with migraine received a physician's diagnosis of migraine [6]. Moreover, merely 2.7% of these individuals had been prescribed preventative medications [6]. Many attempts have been made during the past decade to improve the diagnosis and clinical management of headaches in China, including the establishment of more than 200 headache clinics throughout the country, translation into Chinese of the International Classification of Headache Disorders (ICHD), 2nd edition (ICHD-2) and ICHD-3, publication of guidelines for the diagnosis and clinical management of primary headache disorders, and provision of fundamental training to primary care personnel [7, 8]. However, the effectiveness of these initiatives have not been reevaluated concerning correct diagnosis and preventive treatment of primary headache disorders.

Therefore, we built an inquiry into our recent Survey of Fibromyalgia Comorbidity with Headache (SEARCH) study, designed to assess fibromyalgia's prevalence and clinical features in Chinese hospital patients with primary headache disorders. The additional survey reported here primarily assesses the status of diagnosis and preventative treatment of primary headache disorders in China.

Methods

Study population

This cross-sectional study was a secondary analysis of data from the SEARCH study, the details of which have been described previously [9]. Approval was obtained from the Medical Ethics Committee of Chinese PLA General Hospital (approval number: S2020-238-01), and the study was registered with the Chinese Clinical Trial Registry, with registration number ChiCTR2000034894. Written informed consent was obtained from all participants. Chief complaints of patients during consultation formed the basis of diagnosis for primary headache disorders. Inclusion criteria were consistent with the SEARCH study [9]. Unlike the SEARCH study, patients who had previously used fibromyalgia treatment medication or had incomplete information about their fibromyalgia diagnosis were not excluded from this study. However, participants with missing data in previous diagnosis or prevention history were excluded.

Uniform Questionnaires were used to collect data on sociodemographics (gender, age, race, educational level, individual income, and body mass index), headache characteristics, anxiety, depression, and sleep, in addition to deliberately asking about previous headache diagnosis and prevention treatment. Primary headache disorders were diagnosed according to the ICHD-3 [1]. Detailed information about the questionnaire, and the definition of the variables has been described previously [9]. We classified previous headache diagnoses as "undiagnosed", "migraine", "tension-type headache", "cluster headache", "vascular headache", "nervous headache", or "other" based on the classification of previous headache diagnoses in a previous study [4]. We also explored the previous preventative treatment of patients with the correct diagnosis.

Analysis of baseline characteristics

Analysis was performed using R 4.2.1 (http://www.Rproject.org; The R Foundation, Vienna, Austria) and the Free Statistics software (version 1.8; Beijing FreeClinical Medical Technology Co., Ltd, Beijing, China) [10]. Reg Descriptive statistics include mean (standard deviation), ticip median (interquartile range), and frequencies (percent-

age) as appropriate. We describe the essential characteristics of the overall population and the different primary headache types. In addition, we compared the distribution of comorbidities between groups with delayed diagnosis of primary headache disorders. Differences between the two groups were compared using the chisquare test.


Results

Of the 6,349 patients screened in 23 headache centers, 3,062 did not meet the inclusion criteria, 173 met the exclusion criteria, and 246 lacked data on previous diagnoses (n=176) and prevention history (n=70). Finally, 2,868 participants were included in the final analyses (Fig. 1).

The characteristics of the participants are shown in Table 1. The mean age was 42.1 (12.9) years, and 2,101 (73.3%) were women. 97.6% (2,799/2,868) of the patients were Han Chinese. Regarding educational level, 1,286 (44.8%) participants had a high school or lower. The median headache duration was 8.0 (3.0, 15.0) years.

Regarding headache family history, 1,118 (44.8%) participants had a headache family history. The number of patients with combined anxiety, depression, insomnia, and fibromyalgia were 101 (3.5%), 345 (12.0%), 583 (20.3%), and 157 (5.5%), respectively.

Figure 2 displays the distribution of primary headache disorders. The most prevalent diagnoses were migraine without aura, which accounted for 52.9% (1,516/2,868), followed by chronic migraine (14.9%, 427/2,868), episodic and chronic tension-type headaches (14.9% [427/2,868] and 8.4% [241/2,868] respectively), migraine with aura (6.3%, 181/2,868), cluster headache (1.8%, 52/2,868), other primary headaches (0.7%, 20/2,868), and other TACs (0.1%, 4/2,868). In terms of other primary headache disorders (n=20), primary stabbing headache was the most common (n = 14), with the remaining diagnoses being primary headaches associated with sexual activity (n=1), cough (n=1), cold stimuli (n=1), nummular headaches (n=1), and new daily persistent headaches (n=2). Among the other TACs (n=4), we found shortlasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (n=3) and hemicrania continua (n=1).



Variables	Total (n = 2,868)	Migraine (<i>n</i> = 2,124)	TTH (<i>n</i> = 668)	TACs (n = 56)	Others (<i>n</i> = 20)
Gender, n (%)					
Man	767 (26.7)	484 (22.8)	232 (34.7)	43 (76.8)	8 (40)
Woman	2,101 (73.3)	1,640 (77.2)	436 (65.3)	13 (23.2)	12 (60)
Age, years, Mean (SD)	42.1 (12.9)	40.9 (12.3)	46.2 (13.8)	36.6 (10.8)	43.4 (12.2)
Race ^a , n (%)					
Han	2,799 (97.6)	2067 (97.3)	658 (98.5)	54 (96.4)	20 (100)
Other	66 (2.3)	54 (2.5)	10 (1.5)	2 (3.6)	0 (0)
Educational level ^b , n (%)					
High school	1,286 (44.8)	902 (42.5)	344 (51.5)	26 (46.4)	14 (70)
>High school	1367 (47.7)	1079 (50.8)	256 (38.3)	26 (46.4)	6 (30)
Income per month ^c , n (%)					
<¥ 3000	311 (10.8)	214 (10.1)	92 (13.8)	1 (1.8)	4 (20)
[¥ 3000, ¥ 6000)	437 (15.2)	302 (14.2)	121 (18.1)	10 (17.9)	4 (20)
[¥ 6000, ¥ 9000]	238 (8.3)	177 (8.3)	51 (7.6)	8 (14.3)	2 (10)
>¥ 9000	233 (8.1)	166 (7.8)	57 (8.5)	6 (10.7)	4 (20)
BMI, kg/m ² , Mean (SD)	24.4 (4.7)	24.2 (4.7)	25.0 (4.6)	25.0 (3.5)	25.1 (3.7)
Headache duration, years, Mean (SD)	10.0 (8.7)	10.9 (8.9)	7.5 (7.7)	7.7 (5.4)	4.2 (3.6)
VAS, Mean (SD)	6.3 (1.9)	6.7 (1.7)	4.9 (1.8)	8.1 (1.6)	5.1 (1.8)
Headache family history, n (%)	1,118 (39.0)	948 (44.6)	154 (23.1)	16 (28.6)	0
MOH, n (%)	231 (8.1)	193 (9.1)	38 (5.7)	0	0
Anxiety ^d , n (%)	101 (3.5)	73 (3.4)	27 (4.0)	1 (1.8)	0
Depression ^d , n (%)	345 (12.0)	248 (11.7)	90 (13.5)	5 (8.9)	2 (10.0)
Insomnia ^e , n (%)	583 (20.3)	430 (20.2)	134 (20.1)	14 (25.0)	5 (25.0)
Fibromyalgia, n (%)	157 (5.5%)	112 (5.3%)	43 (6.4)	1 (1.8)	1 (5%)

Abbreviations: TTH Tension-type headache, TACs Trigeminal autonomic cephalalgias, BMI Body mass index, VAS Visual analog scale, MOH Medication overuse headache ^a Data are missing for 3 (0.1%) patients

^b Data are missing for 215 (7.5%) patients

Data are missing for 215 (7.5%) patients

^c Data are missing for 1649 (57.5%) patients

^d Data are missing for one patient

^e Data are missing for 3 (0.1%) patients

The proportion of different previous headache diagnoses is shown in Fig. 3. 56.6% (1,624/2,868) of individuals with primary headache disorders were undiagnosed (Fig. 3E). Specifically, 53.7% (1,141/2,124) of individuals with migraine (Fig. 3A), 66.6% (445/668) of TTH patients (Fig. 3B), 39.3% (22/56) of TACs patients (Fig. 3C), 80% (16/20) of patients with other primary headaches (Fig. 3D), and 41.6% (96/231) of MOH patients (Fig. 3F) were undiagnosed. "Nervous headache" was the most common misdiagnosis among patients with migraine (9.9%, 211/2,124), TTH (10.0%, 67/668), TACs (17.9%, 10/56), and other primary headache disorders (10.0%, 2/20). Of the 231 patients with MOH, 8 individuals (3.5%, 8/231) had a previous diagnosis of MOH. Among those pre-existing primary headache disorders, 31.1% (60/193) of patients were correctly diagnosed with migraine, and 5.3% (2/38) of patients were correctly diagnosed with TTH. Overall, 28.6% of MOH patients had previously been correctly diagnosed with migraine, TTH, or MOH. The previously reported correct diagnosis for migraine, TTH, and TACs was 27.3% (580/2,124), 8.1% (54/668), and 23.2% (13/56), respectively. In patients with TACs, only some cluster headaches (13/52) were correctly diagnosed, while the other's TACs were not.

The proportion of comorbid anxiety (3.5% vs. 3.6%, p = 0.960), depression (12.3% vs. 11.0%, p = 0.346), insomnia (20.7% vs. 19.0%, p = 0.348), and fibromyalgia (5.4% vs. 5.6%, p = 0.909) were similar between the delayed diagnosis group and the non-delayed group (Table S1).

Figure 4 illustrates the prophylactic treatment status of patients previously correctly diagnosed with migraine and TTH. Among the 468 participants with an affirmed medical diagnosis of migraine, only 16.5% (77/468) had taken prophylactic medication previously (Fig. 4A). The most frequently used preventative treatment was calcium-channel blockers, which were used by 77.9% (60/77)




Fig. 2 The proportion of different primary headache types. Other trigeminal autonomic cephalalgias (TACs) included short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing and hemicrania continua. The residual category "Others" included primary cough headache, primary headache associated with sexual activity, primary stabbing headache, cold-stimulus headache, nummular headache, and new daily persistent headache. MO, migraine without aura; MA, migraine with aura; CM, chronic migraine; ETTH, episodic tension-type headache; CTTH, chronic tension-type headache; CH, cluster headache

of the patients (Fig. 5). Out of the 43 patients accurately diagnosed with TTH, only two of them (4.7%) received prophylactic treatment with antidepressants (Fig. 4B). Even though four patients with TACs were accurately diagnosed, none received preventive medicine. Similarly, only one of the eight patients correctly diagnosed with MOH was prescribed prophylactic medication.

Discussion

The rate of correct diagnosis for migraine, TTH, TACs, and MOH recorded previously stood at 27.3%, 8.1%, 23.2%, and 3.5%, respectively. Only 16.5% of individuals accurately diagnosed with migraine and 4.7% of those accurately diagnosed with TTH received prophylactic medication included in the treatment regimen.

The proportion of patients admitted to the hospital outpatient with primary headache disorders shifted regarding the headache type compared to a decade ago. Compared to previous studies in China, migraine disorders increased to 74.1% from 47.6%-49.9%, while the proportion of TTH decreased to 23.3% from 41.5%-47.3% previously [11, 12], suggesting that migraine accounts for most patients presenting to the hospital with primary headache disorders. Similarly, a recent hospital-based study of headache types among headache patients attending outpatient clinics in the Middle East, Asia, and Africa reported that many individuals experienced migraine (57%) compared to TTH patients (32.2%) [13]. The precise cause for the changes in the proportion of individuals with migraine seeking treatment in outpatient clinics remains unclear. We speculate that several factors may have contributed to this shift. One of these factors is the establishment of 31 local headache centers and over 200 headache clinics in China, which have introduced a new era of personalized care for patients suffering from headaches [7]. In addition, to ensure that healthcare professionals are well-informed of the latest advances in the field, comprehensive training courses and headache




Fig. 3 Percentage of previous diagnoses of primary headache disorders and MOH. The cumulative percentage was over 100% due to a patient's multiple previous diagnoses. TTH, tension-type headache; TACs: trigeminal autonomic cephalalgias; CH, cluster headache; MOH: medication overuse headache




Fig. 4 Percentage of previous prophylaxis treatment of migraine (A) and TTH (B). TTH, tension-type headache

conferences have been held in major cities across the country, aimed at providing headache specialists and medical students with the most up-to-date knowledge on all aspects of headache disorders [7]. It is our belief that by implementing these measures, recognition of headache disorders by doctors in China can be improved. Secondly, migraine disorders are typically more severe than TTH, which may encourage individuals with migraine to seek hospital treatment more frequently, thereby explaining why there are more patients with migraine disorders among primary headache patients seen in hospital [14]. Additionally, the current study reported an increase in the correct diagnosis rate for both migraine (from 13.8% to 27.3%) and TTH (from 5.6% to 8.1%) compared to the




Fig. 5 Prophylactic medications previously used by individuals with migraine. The cumulative percentage exceeded 100% due to a patient's previous use of multiple preventative drugs

previous diagnosis rate [4]. However, the increase in correct diagnosis rate was more apparent for migraine than TTH. This suggests that an increased number of individuals with migraine may have been identified as a result of improved diagnostic accuracy. In contrast, TTH may not have received the same benefit from the improvements in diagnostic accuracy, which may have contributed to the observed higher proportion of people with migraine when compared to TTH in the study population.

Misdiagnosis of primary headache disorders continues to influence patients globally (Table 2). Despite an increase in the proportion of accurately diagnosed migraine disorders in China from 13.8% to 27.3% and TTH from 5.6% to 8.1%, the overall correct diagnosis rate remains low [4]. Comparable diagnostic failures of primary headache disorders also occur in other countries. A transcontinental study involving individuals with migraine disorders referred to specialist headache centers showed that general practitioners misdiagnosed 72% of patients with "headaches" (64%), "neck pain" (4%), "tension headache" (3%), and sinusitis (1%) [15]. A secondary analysis of the population-representative 2009 American Migraine Prevalence and Prevention study revealed that 45.5% of individuals with migraine received medical consultation within a year, while 86.7% of the respondents received an accurate migraine diagnosis [16]. A decade later, the OVERCOME 2018 migraine cohort study in the US found that 61.0% of individuals with migraine
 Table 2
 Studies report previous diagnoses and preventative treatment of primary headache disorders

Citation	Country/region	Study design/study dates	Criteria	Population (n)	Main findings	
Liu R, et al. [4]	China	cross-sectional population- based/2009	ICHD-2	452 individuals with migraine and 531 patients with TTH	1.13.8% of individuals with migraine and 5.6% of patients with TTH were cor- rectly diagnosed previously	
Katsarava Z, et al. [23]	10 Europe countries	cross-sectional population- based/2009	ICHD-2	3466 participants with migraine	1.3.1%-18.0% of individuals with migraine have never seen a doctor 2.1.6%-13.7% of eligible patients in the population- based sample used migraine- preventative medication	
Lipton RB, et al. [16]	US	cross-sectional population- based/2009	ICHD-2	775 individuals with migraine	1.45.5% of individuals with migraine disorders con- sulted a health professional in the past year, and 86.7% were diagnosed with migraine	
Li X, et al. [6]	China	cross-sectional neurological clinic/2010	ICHD-2	401 individuals with migraine	1.13.5% of individuals with migraine had received a physician diagnosis of migraine 2. Only 11 (2.7%) individu- als with migraine had used preventative medications	
Lebedeva ER, et al. [18]	Russia	cross-sectional/2012–2013	ICHD-3β	1042 students, 1075 workers, and 1007 blood donors	1.12% of the patients with migraine and 11.7% of patients with TTH had previously been correctly diagnosed 2.0.4% of individuals with migraine and no TTH patients had received prophy- lactic treatment	
Viana M, et al. [15]	Seven countries	multicentre study/2015– 2016	ICHD-3β	1161 individuals with migraine	1. General practitioners mis- diagnosed 72% of individuals with migraine 2.29% of patients received at least one migraine preven- tive medication	
Lipton RB, et al. [17]	US	cross-sectional population- based/2018	ICHD-3	19,888 individuals with migraine	1.12,905 (61.0%) self- reported a medical diagnosis of migraine 2. 41.6% of those eligible for migraine preventive treat- ment currently use migraine preventive medication	
Takeshima T, et al. [19]	China, Japan, and South Korea	review/2019	IHS ICHD-2 ICHD-3β	migraine	1. In China, 13.5% to 18% of individuals with migraine had been diagnosed with migraine previously 2. In Japan, 11.6% of individu- als with migraine were aware that they had migraine 3. There was limited informa- tion in South Korea	
Kim BK, et al. [24]	South Korea	multicentre study/2019	ICHD	207 participants with migraine	1. Only 23.7% of individuals with migraine had regularly taken preventive medication	

ICHD International Classification of Headache Disorders, IHS International Headache Society, TTH tension-type headache

disorders self-reported receiving a medical diagnosis of migraine [17]. In Russia, only 12% of people with migraine and 11.7% of individuals with TTH received a correct diagnosis [18]. Common misdiagnoses included autonomic vascular dysfunctions (56%), cervical osteochondrosis (35%), and intracranial hypertension (10%) [18]. In Japan, a mere 11.6% of participants experiencing migraine were aware that they had migraine [19]. It is estimated that only 13% of individuals with migraine in low-income countries are diagnosed by healthcare professionals [20]. Moreover, this study also provides insights into the previously recorded correct diagnoses of TACs and MOH. The results of this study regarding the prior accurate diagnosis of MOH (3.5%) are in line with an earlier hospital-based study, which reported that very few patients with MOH, 0.8% (2/240), had received a previously correctly diagnosed [21]. When taken together, the total rate of correct diagnosis in primary headache patients and MOH receiving health-care continues to be unfavorable, indicating the need for additional measures to improve it.

Besides misdiagnosis, inadequate preventive treatment for patients with primary headache disorders remains another prevalent concern (Table 2). Our research identified that prior utilization of preventive medication by those with migraine and TTH was recorded at 16.5% and 4.7%, respectively. In comparison, another report from a clinical setting indicated the usage to be only 2.7% of individuals with migraine [6]. In Chinese Taiwan, 40.2% of migraine outpatients reported using preventive medicines [22]. Correspondingly, the Eurolight study -a cross-sectional questionnaire survey- conducted in ten European countries uncovered that only 1.6-13.7% of eligible individuals in a population-based European sample utilized preventative medication for migraine disorders [23]. Likewise, in Russia, prophylactic medication was used by only 0.4% of individuals with migraine and zero TTH patients [18]. The OVERCOME study findings in the US stated that although eligibility, 41.6% of those utilizing migraine preventive medication, was revealed [17]. For South Korea, only 23.7% of individuals with migraine disorders reportedly used preventive medication regularly [24]. Taken together, it can be concluded that the prevalence of preventive medication use remains low among people with migraine worldwide, even in countries with high-income levels [23].

A literature review with meta-analysis has shown that patients with primary headache disorders are often comorbid with depression, anxiety, sleep disorders, and fibromyalgia, and this finding was also observed in the present study [25]. 5.5% of individuals with migraine had comorbid fibromyalgia in our study, which is consistent with the findings (5.09%) of Patel et al. [26]. Additionally, previous study demonstrated that migraine is a triggering factor for fibromyalgia, suggesting that in individuals with migraine we should screen for the co-existence of fibromyalgia [27]. Overall, it is the fact that primary headache sufferers are prone to comorbidities that makes it even more challenging to properly diagnose primary headache patients, which can be read as a litmus test of the ability to correctly diagnose primary headaches.

This study exhibits multiple noteworthy strengths, including its large sample size and multicenter design. Additionally, the ICHD-3 version was adapted to aid in diagnosing primary headache disorders. Nevertheless, several limitations require consideration. Firstly, the exclusive study of hospital patients may lead to biased results and limited generalizability. Secondly, diagnosis focusing on the most troublesome headache features may neglect to co-occur primary headache disorders. Thirdly, the obtained data regarding previous diagnoses and preventative treatments were participants to self-reporting, which can lead to recall bias. Fourth, we did not analysis further the factors affecting delayed diagnosis and the duration of delayed diagnosis. The headache questionnaire used in the SEARCH study was a reference to previous questionnaires investigating the burden of headache in China [4, 5, 28]. Moreover, the SEARCH study was not specifically designed to address the current state of primary headache disorders care in China, and therefore did not collect information that affects the correct diagnosis of primary headache and the duration of diagnostic delay. Finally, the classification of previous headache diagnoses in this study was not based on the International Headache Classification, but on the diagnostic classification used in previous study in China [4]. Therefore, the classification of previous headache diagnoses cannot be generalized to other countries.

Conclusions

Our study's findings indicate that primary headache disorders are frequently misdiagnosed and inadequately treated, pointing to insufficient use of ICHD guidelines and other diagnostic and clinical management protocols in China. These results highlight the pressing need for sustained campaigns and educational efforts worldwide to improve the diagnosis and treatment of primary headache disorders.

Abbreviations

TTH	Tension-type headaches
TACs	Trigeminal autonomic headaches
MOH	Medication overuse headaches
ICHD	International classification of headache disorders
SEARCH	Survey of fibromyalgia comorbidity with headache

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s10194-023-01654-6.

Additional file 1: Table S1. Distribution of comorbidities in the diagnostic delay group in primary headache disorders.

Acknowledgements

We thank all the patients who took part in the study.

Authors' contributions

HXL, MD, KML, ZHJ, WG, YYC, YDL, KQ, HRZ, JJC, DZ, ZLF, XSY, DMH, HYX, MXL, BW, SFC, PX, QQR, QH, ZXR, FHY, HLZ, MC, TMY, HLQ, XKA, HLG, XHZ, XPP, XJW, SQ, LMZ, HLZ, XP, QW, LYY, JL, ZY, MJZ, YR, and XH collected, analyzed and interpreted the data and results, and drafted the manuscript. HXL, MD, ZD, and SYY revised the manuscript. SYY and ZD proposed the concept and design of the study and revised manuscript for critical intellectual content. HXL and ZD revised manuscript for critical intellectual content. All authors had access to the data. All authors read and approved the final manuscript.

Funding

This work was supported by Health Special Research Projects (grants 22BJZ21) and National Natural Science Foundation of China (grants 82171208).

Availability of data and materials

The study data are available and may be shared upon reasonable request to the corresponding authors.

Declarations

Ethics approval and consent to participate

Approval was obtained from the Medical Ethics Committee of Chinese PLA General Hospital (approval number: S2020-238–01), and the study was registered with the Chinese Clinical Trial Registry, with registration number ChiCTR2000034894. Written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that there is no conflict of interest.

Author details

¹Department of Neurology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.²International Headache Center, Chinese PLA General Hospital, Beijing 100853, China. ³Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Jilin 130021, China. ⁴Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang 310009, China. ⁵Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road 17, Hefei 230001, China. ⁶Department of Neurology, The First Affiliated Hospital of Soochow University, Jiangsu 215006, China. ⁷Department of Neurology, Lishui Municipal Central Hospital, Zhejiang 323000, China. ⁸Department of Neurology, Sir Run Run Shaw Hospital, Zhejiang 310020, China. ⁹Department of Neurology, Xing Tai People's Hospital, Hebei 054001, China. ¹⁰Department of Neurology, Xiangya Hospital, Central South University, Hunan 410013, China. ¹¹Department of Neurology, The Second Affiliated Hospital of Shandong First Medical University, Shandong 271000, China. ¹²Department of Neurology, Qilu Hospital, Shandong 250012, China.¹³Department of Neurology, Changsha Central Hospital Affiliated to the University of South China, Hunan 410004, China. ¹⁴Department of Neurology, Affiliated Hospital of Jining Medical University, Shandong 272000, China. ¹⁵Department of Neurology, The People's Hospital of Liaoning Province, Liaoning 110016, China. ¹⁶Department of Neurology, Linyi Jinluo Hospital, Shandong 276036, China. ¹⁷Department of Neurology, Zhengzhou University First Affiliated Hospital, Henan 450052, China. ¹⁸Department of Neurology, The Second Hospital of Jilin University, Jilin 130041, China.

¹⁹Department of Neurology, The First Affiliated Hospital of Xiamen University, Jilin 130041, China. ²⁰Department of Neurology, People's Hospital, Peking University, Beijing 100044, China. ²¹Department of Neurology, Guangzhou First People's Hospital, Guangdong 510180, China. ²²Department of Neurology, Aerospace Center Hospital, Beijing 100049, China. ²³Department of Neurology, Da Lian Municipal Central Hospital, Liaoning 116033, China. ²⁴Department of Neurology, Jiangsu Province Hospital, Jiangsu 210029, China.

Received: 26 May 2023 Accepted: 15 August 2023 Published online: 01 September 2023

References

- Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1–211
- Saylor D, Steiner TJ (2018) The global burden of headache. Semin Neurol 38(2):182–190
- Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A et al (2021) Migraine: epidemiology and systems of care. Lancet 397(10283):1485–1495
- Liu R, Yu S, He M, Zhao G, Yang X, Qiao X et al (2013) Health-care utilization for primary headache disorders in China: a population-based doorto-door survey. J Headache Pain 14(1):47
- Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J et al (2012) The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache 52(4):582–591
- Li X, Zhou J, Tan G, Wang Y, Ran L, Chen L (2012) Diagnosis and treatment status of migraine: a clinic-based study in China. J Neurol Sci 315(1–2):89–92
- 7. Yu S, Zhang M, Zhou J, Liu R, Wan Q, Li Y (2014) Headache care in China. Headache 54(4):601–609
- Yu S, Steiner TJ (2017) Lifting the burden of headache in China: managing migraine in a SMART way. J Headache Pain 18(1):79
- Dong Z, Liu K, Liu H, Jia Z, Gui W, Dong M et al (2023) The prevalence and clinical features of fibromyalgia in Chinese hospital patients with primary headache: the survey of fibromyalgia comorbid with headache. Headache 63(1):62–70
- Yang Q, Zheng J, Chen W, Chen X, Wen D, Chen W et al (2021) Association between preadmission metformin use and outcomes in intensive care unit patients with sepsis and type 2 diabetes: a cohort study. Front Med (Lausanne) 8:640785
- 11. Dong Z, Di H, Dai W, Liang J, Pan M, Zhang M et al (2012) Application of ICHD-II criteria in a headache clinic of China. PLoS One 7(12):e50898
- 12. Wang Y, Zhou J, Fan X, Li X, Ran L, Tan G et al (2011) Classification and clinical features of headache patients: an outpatient clinic study from China. J Headache Pain 12(5):561–567
- Genc H, Baykan B, Bolay H, Uluduz D, Unal-Cevik I, Kissani N et al (2023) Cross-sectional, hospital-based analysis of headache types using ICHD-3 criteria in the Middle East, Asia, and Africa: the Head-MENAA study. J Headache Pain 24(1):24
- 14. Gupta R, Bhatia MS (2011) Comparison of clinical characteristics of migraine and tension type headache. Indian J Psychiatry 53(2):134–139
- Viana M, Khaliq F, Zecca C, Figuerola MDL, Sances G, Di Piero V et al (2020) Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. Eur J Neurol 27(3):536–541
- Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC (2013) Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 53(1):81–92
- 17. Lipton RB, Nicholson RA, Reed ML, Araujo AB, Jaffe DH, Faries DE et al (2022) Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache 62(2):122–140
- Lebedeva ER, Kobzeva NR, Gilev DV, Olesen J (2017) The quality of diagnosis and management of migraine and tension-type headache in three social groups in Russia. Cephalalgia 37(3):225–235
- Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, Rajan N et al (2019) Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain 20(1):111

- 20. WHO (2011) Lifting The Burden. Atlas of headache disorders and resources in the world 2011. Available from: https://www.who.int/mental_health/management/atlas_headache_disorders/en/
- Dong Z, Chen X, Steiner TJ, Hou L, Di H, He M et al (2015) Medicationoveruse headache in China: clinical profile, and an evaluation of the ICHD-3 beta diagnostic criteria. Cephalalgia 35(8):644–651
- Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K (2013) Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia 33(3):171–181
- Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ (2018) Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain 19(1):10
- Kim BK, Chu MK, Yu SJ, Dell'Agnello G, Han JH, Cho SJ (2021) Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain 22(1):45
- Caponnetto V, Deodato M, Robotti M, Koutsokera M, Pozzilli V, Galati C et al (2021) Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain 22(1):71
- Patel UK, Malik P, Sheth R, Malhi P, Kapoor A, Saiyed BMRS et al (2019) Fibromyalgia and myositis linked to higher burden and disability in patients with migraine. SN Compr Clin Med 1:882–90
- 27. Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D et al (2015) Impact of migraine on fibromyalgia symptoms. J Headache Pain 17:28
- Yu SY, Cao XT, Zhao G, Yang XS, Qiao XY, Fang YN et al (2011) The burden of headache in China: validation of diagnostic questionnaire for a population-based survey. J Headache Pain 12(2):141–146

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

